A Multicenter, Open-label Extension Study To Evaluate The Long Term Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy

Trial Profile

A Multicenter, Open-label Extension Study To Evaluate The Long Term Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Domagrozumab (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 05 Jul 2017 Planned End Date changed from 3 Feb 2023 to 13 Mar 2023.
    • 05 Jul 2017 Planned primary completion date changed from 3 Feb 2023 to 13 Mar 2023.
    • 06 Jun 2017 Planned End Date changed from 29 Mar 2021 to 3 Feb 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top